Problem: Trading in influence, or influence peddling, refers a person selling his/her influence over the decision making process to benefit a third party (person or institution). The difference with bribery is that this is a tri-lateral relation. From a legal point of view, the role of the third party (who is the target of the influence) does not really matter although he/she can be an accessory in some instances. It can be difficult to make a distinction between this form of corruption and some forms of extreme and loosely regulated lobbying where for instance law- or decision-makers can freely "sell" their vote, decision power or influence to those lobbyists who offer the highest compensation, including where for instance the latter act on behalf of powerful clients such as industrial groups who want to avoid the passing of specific environmental, social, or other regulations perceived as too stringent, etc. Where lobbying is (sufficiently) regulated, it becomes possible to provide for a distinctive criteria and to consider that trading in influence involves the use of "improper influence", as in article 12 of the Criminal Law Convention on Corruption (ETS 173) of the Council of Europe.
Selling or trading government position influence is called what?
---
Answer: influence peddling


Problem: Others have argued that excessive regulation suppresses therapeutic innovation, and that the current cost of regulator-required clinical trials prevents the full exploitation of new genetic and biological knowledge for the treatment of human disease. A 2012 report by the President's Council of Advisors on Science and Technology made several key recommendations to reduce regulatory burdens to new drug development, including 1) expanding the FDA's use of accelerated approval processes, 2) creating an expedited approval pathway for drugs intended for use in narrowly defined populations, and 3) undertaking pilot projects designed to evaluate the feasibility of a new, adaptive drug approval process.
What was argued to be holding back new knowledge for treating diseases?
---
Answer: current cost of regulator-required clinical trials


Problem: Small, cheap discoidal ceramic capacitors have existed since the 1930s, and remain in widespread use. Since the 1980s, surface mount packages for capacitors have been widely used. These packages are extremely small and lack connecting leads, allowing them to be soldered directly onto the surface of printed circuit boards. Surface mount components avoid undesirable high-frequency effects due to the leads and simplify automated assembly, although manual handling is made difficult due to their small size.
 What is one inconvenience of using surface mount components?
---
Answer:
unanswerable